Effective vaccines against genital herpes simplex virus type 2 (HSV-2) may need to induce genital tract immune responses. To determine local antibody responses to HSV-2 glycoproteins gB2 and gD2 in an intramuscular subunit vaccine, cervical secretions from HSV-seronegative women and HSV-1 -seropositive women were tested for IgG and IgA to gB2 and gD2 by enhanced chemiluminescence Western blot. Most (94%) of the seronegative subjects developed cervical IgG to gB2, IgG to gD2, and IgA to gB2; 72% developed IgA to gD2. All HSV-1 -seropositive subjects had cervical IgG responses to vaccine gB2 and gD2, 85% had IgA responses to gB2, and 50% had IgA responses to gD2. Responses were more rapid and titers more consistently sustained in the HSV-1 -seropositive women. Further, vaccination resulted in cervical IgG and IgA titers comparable to those to HSV-2 gB2 and gD2 in response to recurrent HSV-2 genital infection.
Genital herpes continues to spread, partly because of the Here we report the isotype and kinetics of cervical antibody development after each of three intramuscular doses of an high proportion of subclinical or unrecognized cases and the frequency of viral shedding in the absence of symptoms [1] .
HSV-2 subunit vaccine. Eighteen HSV-seronegative women and 20 women with prior HSV-1 immunity completed a protoThat prior immunity to herpes simplex virus (HSV) gives at least partial protection against infection is inferred from obsercol to receive three doses of vaccine. Their responses were compared to determine the effects of prior mucosal priming vations that genital infection with ú1 strain of HSV-2 is rare [2] , that acquisition of genital herpes is lower in subjects with (in the subjects with prior HSV-1) on local antibody development after parenteral boosting. prior HSV-1 antibodies than in HSV-naive patients [3] , and that vertical transmission of genital HSV-2 to the newborn is infrequent from mothers with established infection [4] . These findings suggest that vaccine-induced immunity could be an Materials and Methods effective means of slowing the spread of genital herpes. BeSubjects. Women aged 18-55 years were recruited, enrolled, cause HSV infections begin at mucosal sites, induction of a and followed up at the University of Washington Virology Reconsistent local antibody response is a desirable characteristic search Clinic. Women were not pregnant at entry, agreed to use of any candidate vaccine for HSV. reliable birth control methods throughout the study, and were huPreviously we characterized cervical antibody responses to man immunodeficiency virus-negative. Subjects were tested for first episodes of genital herpes in women. These studies showed the presence of HSV-1 and HSV-2 serum antibodies by Western a predominant IgG response to viral protein antigens similar blot [7] .
to those of serum antibodies. However, HSV-specific IgA reTwenty HSV-seronegative women and 20 HSV-1-seropositive sponses differed qualitatively from cognate serum IgA rewomen were enrolled. Further serologic testing by a more sensitive technique [8] confirmed that 19 women lacked antibodies to HSVsponses [5] . We also demonstrated local anamnestic antibody 1 and HSV-2, providing serologic evidence that they had not been responses in the cervix when HSV-1 -seropositive women acinfected with either HSV subtype. This additional testing revealed quired genital HSV-2 infections [6] . that 1 subject who was HSV-seronegative by standard screening assay had a low titer of antibodies to HSV-1. This person, therefore, was included in the HSV-1-seropositive group, giving 19 by Western blot in parallel with sera drawn at the start of the trial test artifacts that prevented accurate IgA assessment. Of 18 day 0 specimens from subjects that were tested for cervical IgG, 14 to detect serologic evidence of HSV-2 infection in all subjects and of HSV-1 infection in the HSV-seronegative subjects during the (78%) were positive for gD2 and 12 (67%) for gD2. As shown previously, HSV-1 infection results in detectable cervical antibodtrial. None of the subjects was found to have seroconverted to HSV-1 or HSV-2.
ies to gB2 and gD2 because of the extensive cross-reactivity of these proteins between HSV-1 and HSV-2 [6] . Cervical secretions from 11 subjects who were seronegative for HSV by enhanced chemiluminescence Western blot (ECL-WB)
Titer determination by strip immunoblot assay. Cervical secretions were serially diluted 4-fold in 4% goat serum in PBS starting [8] were pooled to use as background control samples in the ECL-WB test. An additional 6 control subjects were HSV-2-seroposiat a dilution of 1:20 for IgA and at 1:80 for IgG. Custom nitrocellulose strips containing bands of nondenatured recombinant gB2 and tive with histories of culture-documented recurrent genital herpes lesions. Cervical and vulvar samples from these HSV-2-seroposigD2 were provided by Chiron Vaccines. Strips were incubated for 1 h in 0.5 Tween 20 in PBS, and then used as described [5] . Strips tive control subjects were further characterized by HSV polymerase chain reaction as being negative for HSV shedding at the time were exposed to film for 30 s and then for periods ranging from 2 s to 2 min. End-point titers were taken as the reciprocal of the of cervical sampling.
Sampling. Cervical samples were collected on days 0, 28, 42, highest dilution showing a clear gB2 or gD2 band at the selected exposure time, as shown for cervical IgG ( figure 1A ) and cervical 90, 180, 194, 270, and 360 and 14 days after the fourth dose. As described in detail [5] , two sequential pairs of tear flow indicator IgA ( figure 1B ) from 1 HSV-1-seropositive subject. The test was repeated if titer determinations of two readers were not in agreestrips were placed in the cervical os until secretions had soaked up to the strips' shoulders. After trimming, the four saturated stubs ment. By comparing end-point titers with those generated by humanized monoclonal antibodies of known concentration (see bewere placed in a vial with 0.5 mL of 0.01% sodium azide in PBS low), we estimate that a cervical IgG titer of 1:80 represents Ç78 and frozen at 020ЊC. Serum was obtained at each clinic visit and ng/mL IgG to gB and 313 ng/mL IgG to gD. stored at 020ЊC.
Humanized IgG monoclonal antibodies against gB2 and gD2 Local antibody testing. Samples were processed as described (provided by R. Whitley, University of Alabama, Birmingham) previously [5] ; none was positive for blood (Hemoccult; Smithwere used to select films for end-point determination. Monoclonal Kline Diagnostics, San Jose, CA).
antibodies were serially diluted 4-fold in 4% goat serum in PBS Samples were tested by ECL-WB using recombinant gB2 and starting at 1:4000 and reacted with assay strips as described above. gD2 as the antigens [8] . Because the recombinant proteins con-A monoclonal antibody test was run with each subject's secretions. tained several species with similar electrophoretic mobilities, gB2
The exposure time for the film to be used for end-point determinaand gD2 were run on separate gels. Twenty microliters of each tion was determined by comparing the monoclonal antibody band cervical sample was diluted 1:50 in Blotto and incubated with blots intensity at each dilution with that of an external reference standard overnight at room temperature. Blots were washed, and bound run. Films were selected to be as close as possible in intensity of antibodies were detected with goat anti-human IgA (a chain) or these control bands to minimize reading artifact ( figure 1C ). goat anti-human IgG (g chain) and ECL detection reagents (AmerStatistical methods. The proportions of seronegative and HSVsham Life Sciences, Oakville, Canada) [5] .
1-seropositive subjects having an IgG and IgA response to the Samples from days 0 to 270 (8 samples) from a single subject vaccine glycoproteins were compared by cross-tabulation, with were run in the same immunostaining run on blots derived from statistical significance based on x 2 or Fisher's exact test. a single gel containing gB2 and a second gel containing gD2. A IgA values õ1:20 and IgG values õ1:80 were assigned values second set of blots was used for days 360 and 374 to assess of 1:10 and titers were log 10 transformed for these analyses. Georesponses to the fourth dose. Blots were exposed to film for periods metric mean titers are presented along with their SDs. Because of from 10 s to 4 min. Film profiles were selected for scoring, using the presence of outliers or extreme values for some samples, the the maximal film exposure time that gave discrete banding in nonparametric Wilcoxon-Mann-Whitney test was used to calcuthe lane developed with a cervical secretion control pool from late statistical significance of differences between groups (e.g., unvaccinated HSV-2-seropositive subjects. Most profiles were seseronegative vs. seropositive.) The Wilcoxon signed ranks test was lected for scoring from 1-min exposures (IgA) or 30-s exposures used to compare paired values within a group (e.g., titers before (IgG).
and after a dose). Profiles were scored as positive for vaccine-related response in
The Spearman correlation coefficient was used to determine if seronegative subjects if vaccine bands were detectable 28 days serum and cervical IgG responses tended to change together over after the first vaccine dose and 14 days after subsequent doses time. For each subject, the Spearman correlation coefficient becompared with the profile of cervical secretions from the same tween paired values (serum, cervical) was calculated for all obsersubject just before that immunization. Profiles were scored as posivation times. The correlation ranged between 0.0 and {1.0, repretive for vaccine-related responses in HSV-1-seropositive subjects senting no correlation and perfect correlation (positive or negative), if vaccine bands appeared de novo or increased in intensity in respectively. The Wilcoxon signed ranks test was used to test the blots of secretions taken 28 days after the first vaccine dose comnull hypothesis that the mean correlation is zero, that is, that serum pared with the day 0 sample and 14 days after subsequent doses of and cervical responses are unrelated. vaccine compared with profiles of secretions collected immediately before that immunization. tions were compared for evidence of responses to gB2 or gD2. increased in intensity at day 42 and was therefore scored as a response. Comparing day 194 and day 180 profiles resulted in Appearance of a new band in the gB2 or gD2 location of the blot or increased band intensity of secretions taken after scoring an IgG response to both gB2 and gD2 given in dose 3. This subject demonstrated decreased levels of IgG and IgA vaccination compared with the day of vaccination was scored as a response to that particular vaccine dose.
Results

Of
at day 270, suggesting a waning of titers 3 months after the third dose. Cervical antibody responses to the vaccine proteins were observed in most subjects, but not necessarily to each dose. Of All of this subject's post-dose profiles at day 28, 42, and 194 have antibody not detected at day 0, before immunization. the 18 seronegative subjects who received three doses, 17 (94%) had IgG responses to gB2 in at least 1 pair of samples.
However, with IgA in particular, intensity of gB2 bands did not change dramatically once a response was noted. Responses For the other antibody responses, 17 pairs could be evaluated. Sixteen (94%) of 17 seronegative subjects developed IgG to to the fourth dose were determined in paired day 360 and day 374 secretions analyzed at a later date with a second set of gD2 and IgA to gB2 after at least one dose; 13 (72%) of 17 developed IgA responses to gD2 that were detected in at least blots. IgG or IgA responses were not apparent to gB2 or gD2 1 pair of samples. Responses to dose 4 in the 14 seronegative subjects were less prevalent than to earlier doses (table 1) .
The responses to individual doses 2, 3, and 4 represented figure 3A) . Mean end point titers for specimens taken at days 90 and 180 (between doses 2 and 3) showed progressive waning of antibody titers ( figure 3A) . Similarly, mean titers dropped by day 360 between the third and fourth doses ( figure 3A) . Thus, in seronegative subjects, the third and fourth doses did not boost antibody titers above those achieved with two doses but, rather, served to partially or fully restore titers that had waned.
Cervical IgG and IgA responses to vaccine in seropositive subjects. All of the 20 seropositive subjects receiving three doses had increased cervical IgG band intensities of gB2 and gD2 after one to three doses. Seventeen (85%) of 20 subjects had increased levels of cervical IgA to gB2 and 10 (50%) developed additional IgA to gD2 after at least one dose. A higher proportion of subjects responded to the first dose than to later doses (table 2) .
Response patterns differed between seronegative and HSV-1 -seropositive subjects in the following ways: A higher proportion of HSV-1 -seropositive than seronegative subjects had responses to the first dose (P õ .01 for IgG to gB2 and gD2). In contrast, a higher proportion of seronegative subjects had specimens collected on days 0, 14, 28, 42, and 90. In this subject, IgG and IgA were present to both gB2 and gD2 before vaccination (day 0). Both IgG and IgA titers increased by day in the subject illustrated in figure 2 ; however, IgG to gB2 and gD2 and IgA to gB2 are clearly shown compared with day 0 14. IgA titers waned; day 42 titers did not recover to day 14 levels after a second dose. Similarly, IgG titers at day 42 did preimmunization profiles.
Magnitude and duration of cervical IgG and IgA responses not reflect a response to the second dose given at day 28. In the seropositive subjects, geometric mean IgG titers rose in seronegative subjects. Examination of blots such as those in figure 2 revealed that in many cases, responses to doses 3 after dose 1 and remained quite constant thereafter ( figure 3B ). Mean titers of IgA in seropositive subjects rose after the first or 4 did not dramatically increase the band intensity seen after dose 1 or 2. It appeared that doses beyond 2 in seronegative dose and remained relatively constant except for slight titer decreases before the third dose (day 180) and before the fourth subjects served more to restore waning levels of antibodies than to boost antibody levels beyond those derived from prior dose (day 360). Thus, HSV-1 -seropositive subjects had less dramatic fluctuations in titers over the course of the vaccination doses. However, since observation of blot profiles is not quantitative, we attempted to confirm this impression by determining protocol than did seronegative subjects. Titers of cervical antibodies to vaccine versus natural infecend-point titers for the subset of seronegative subjects with sufficient residual samples.
tion. Western blots from this study had gB2 and gD2 band intensities that were similar to or more intense than those proIncreases in mean log 10 titers were observed for both IgG and IgA against both proteins for all doses ( figure 3A) . Mean duced by cervical specimens from patients with genital herpes, suggesting that vaccine responses were comparable in titer with titers were higher at the end of the trial (after three doses) than after the first dose for IgG and IgA to both gB2 and gD2. Titers those elicited by mucosal infection. To test this hypothesis, end-point titers after three doses (day 194) were compared with after three doses were equal to or slightly lower than after the second dose. The fourth dose did not result in higher geometric those obtained from women with culture-documented recurrent / 9d4a$$jy38 05-15-98 07:16:33 jinfa UC: J Infect HSV-2 infections. The HSV-2 -infected subjects were sampled than in either the seronegative vaccine recipients (P õ .01 for IgG to gB2 and P õ .05 for IgG to gD2) or the HSV-2 -for cervical antibodies and, at the same visit, by polymerase chain reaction testing to detect HSV DNA. Only samples taken infected subjects (P õ .01 for IgG to gB2 and gD2). There was a trend toward higher IgA titers in HSV-1 -seropositive at times when HSV DNA was not detected were used in this comparison to avoid bias introduced by local antigen-antibody vaccine recipients than in either seronegative or naturally infected subjects. IgG and IgA titers of the infected subjects were complexes, which would not be detected by the strip immunoblot system. Titers from 8 seronegative vaccine recipients, somewhat higher than those of seronegative vaccine subjects, but the differences were not statistically significant. from 18 HSV-1 -seropositive vaccine recipients, and from 9 naturally HSV-2 -infected subjects were compared (table 3) .
Comparison of cervical and serum IgG titers. This study offered the unique opportunity to explore the relationship beMean titers of IgG and IgA to gB2 and gD2 were significantly higher in the HSV-1 -seropositive vaccine recipients tween serum responses and the development of cervical anti-/ 9d4a$$jy38 05-15-98 07:16:33 jinfa UC: J Infect Serum and cervical responses over time showed a moderate sudation has been described but was not applied in these studies but highly significant mean correlation in both HSV-1 -sero- [18] . positive and HSV-seronegative subjects. In each group, correlaPassive immunization with serum IgG has been shown to tions of serum and cervical IgG to gB2 and correlations of be protective against vaginal challenge with HSV in mice [19] . serum and cervical IgG to gD2 were about equal. The Spearman It has been suggested that in humans, threshold serum IgG correlation for serum and cervical IgG to gB2 in the seronegalevels induced by vaccines against mucosal pathogens are most tive group was .72 { .27 (mean { SD) with 12 patients, yieldclosely correlated with protection [20] . Additional study will ing P Å .002, to reject the null hypothesis of zero correlation.
be needed to determine the function of the IgG identified in For serum and cervical IgG to gD2, the correlation was very this study. similar: n Å 11, r Å .79 { .20, P Å .003. In the seropositive Cervical IgA to the subunit vaccine was less prevalent than group, the correlations between serum and cervical titers were IgG and lower in titer than cervical IgG. The methods used somewhat weaker but still significant: for IgG to gB2, n Å 18, for this study did not identify different molecular forms of IgA r Å .39 { .24, P õ .001; for IgG to gD2, n Å 19, r Å .36 { .42, (dimeric versus monomeric), nor were we able to determine if P Å .004. These correlations indicate that serum and cervical the IgA detected contained secretory component, a covalently antibody titers changed, in concert, over time.
bound moiety obtained via active transport and maturation of dimeric IgA into the mucosal lumen. Because the serum EIA Discussion did not measure IgA, we could not determine if the fluctuations in IgA titers reflected serum IgA fluctuations. Thus, while IgA We report here that intramuscular injections of an HSV-2 subunit vaccine result in cervical IgG and IgA to both of the appears to constitute a substantial minority of the immunoglob- Seronegative vaccine recipients 2.7 { 1.2* (n Å 8) 2.9 { 1.4 † (n Å 7) 1.9 { 0.7 (n Å 6) 2.2 { 1.1 (n Å 8) Seropositive vaccine recipients 3.9 { 0.4* ‡ (n Å 18) 3.9 { 0.4 † ‡ (n Å 18) 2.7 { 0.8 (n Å 18) 2.7 { 0.8 (n Å 18) Subjects with HSV-2 infection 3.2 { 0.6 ‡ (n Å 9) 3.3 { 0.6 ‡ (n Å 9) 2.4 { 0.7 (n Å 9) 2.4 { 1.2 (n Å 9)
NOTE. Data are geometric mean cervical log 10 end-point titers ({ SD). * P õ .01 between seronegative and seropositive groups. † P õ .05 between seronegative and seropositive groups. ‡ P õ .01 between seropositive and infected groups.
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